Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Stopped All patients past planned primary endpoint; decision by Sponsor to wind down open-label follow-up activities.

Conditions

• Wet Age-related Macular Degeneration
• Retinal Vein Occlusion
• Diabetic Macular Edema

Interventions

• DRUG: KSI-301

Sponsor

Kodiak Sciences Inc